Sodium nitrite oral - Theravasc
Alternative Names: JAN-101; JAN101 SR; TV-1001; TV1001SRLatest Information Update: 24 Nov 2023
At a glance
- Originator LSU Health Shreveport
- Developer TheraVasc; University of Colorado at Boulder
- Class Antidotes; Antihypertensives; Antivirals; Nitrites; Small molecules; Sodium compounds; Vascular disorder therapies; Vasodilators
- Mechanism of Action Membrane fusion protein inhibitors; Nitric oxide donors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diabetic neuropathies; Peripheral arterial disorders
- Phase I/II Vascular disorders
- No development reported Systemic scleroderma
Most Recent Events
- 21 Sep 2023 Efficacy data from a phase II trial in Diabetic neuropathies in USA (PO) released by TheraVasc
- 01 Aug 2023 University of Alabama at Birmingham plans a phase I trial for pain in August 2023 (PO) (NCT05893160)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Systemic-scleroderma in USA (PO)